BioNTech SE (NASDAQ:BNTX) Holdings Decreased by Mackenzie Financial Corp

Mackenzie Financial Corp reduced its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 83.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,903 shares of the company's stock after selling 19,370 shares during the quarter. Mackenzie Financial Corp's holdings in BioNTech were worth $445,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in BNTX. FMR LLC lifted its stake in shares of BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after purchasing an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE lifted its stake in shares of BioNTech by 1.1% in the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock valued at $502,160,000 after purchasing an additional 47,236 shares in the last quarter. Capital International Investors lifted its stake in shares of BioNTech by 38.6% in the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after purchasing an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets acquired a new position in shares of BioNTech in the 4th quarter valued at about $69,999,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of BioNTech by 632.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 501,897 shares of the company's stock valued at $57,191,000 after purchasing an additional 433,388 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Down 1.5%

BNTX stock traded down $1.66 during midday trading on Friday, hitting $108.49. 1,135,854 shares of the company's stock were exchanged, compared to its average volume of 943,103. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a 50 day moving average price of $99.26 and a 200-day moving average price of $108.35. The stock has a market capitalization of $26.08 billion, a price-to-earnings ratio of -51.66 and a beta of 1.29.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the previous year, the business earned $1.90 EPS. BioNTech's revenue for the quarter was down 19.5% compared to the same quarter last year. On average, analysts anticipate that BioNTech SE will post -3.88 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BNTX. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday. The Goldman Sachs Group began coverage on BioNTech in a research note on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price objective on the stock. Leerink Partners set a $112.00 price objective on BioNTech in a research note on Monday, June 2nd. HC Wainwright boosted their price target on BioNTech from $134.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Citigroup reissued a "buy" rating and set a $140.00 price target (down from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $138.25.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.